MedPath

Vitrification Versus Slow Cooling of Human Cleavage Stage Embryos

Not Applicable
Terminated
Conditions
Infertility
Interventions
Other: embryo vitrification
Registration Number
NCT00886431
Lead Sponsor
UMC Utrecht
Brief Summary

Human embryos can be preserved for later transfers by freezing. Traditionally the slow cooling method has been used. About 70% of the embryos remain fully intact after thawing. However, the remaining 30% of the embryos become (partially) damaged, and this freezing damage reduces their chance to implant. Recently an ultra rapid freezing method, called vitrification has been developed. During vitrification no damaging ice crystals are formed and the embryo freezes in a glass like state.

It appears that the freezing damage is reduced when embryos are vitrified. Observational studies in humans indicate that embryos are successfully preserved by vitrification, as indicated by promising pregnancy rates following thawing. However, the effectiveness of vitrification in relation to slow cooling with respect to pregnancy rates has so far not been evaluated by a randomised, controlled trial. The aim of this study is to investigate whether vitrification significantly improves embryo survival and ongoing pregnancy rates when compared to embryos frozen by slow cooling.

Detailed Description

time of allocation: following embryo selection

type of embryos: cleavage stage -, morula stage or early blastocyst stage embryo (day3 - day4 after oocyte collection)

cryoprotectants: sucrose, dimethylsulfoxide, ethyleneglycol

vitrification storage device: high security vitrification straws

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
146
Inclusion Criteria
  • female patient age 35 years or less
  • embryos are obtained by in vitro fertilization (IVF) or intra cytoplasmatic spermatozoon injection (ICSI)
  • single embryo transfer
  • 1rst IVF/ICSI treatment with an embryo transfer
  • availability of cryopreservable embryos
Exclusion Criteria
  • female patient age is 36 years or older
  • participants of oocyte donation program
  • participants of percutaneous spermatozoon aspiration (PESA) program
  • couples with a finite source of spermatozoa
  • absence of cryopreservable embryos

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Vitrificationembryo vitrificationThe embryos of patients allocated to this arm will be cryopreserved by vitrification.
Primary Outcome Measures
NameTimeMethod
The percent change of the ongoing pregnancy rate per patient/couple who use their thawed embryos (following a fesh embryo transfer which did not result in an ongoing pregnancy) from baseline (slow cooling) to end point (vitrification).ongoing pregnancy is established 10 weeks following the transfer of a frozen embryo
Secondary Outcome Measures
NameTimeMethod
post-thaw embryo survival rate1 hour after thawing
implantation rate per thawed embryo10 weeks after transfer of thawed embryo
cumulative implantation rate per cryopreservation10 weeks after thawed embryo transfer
ongoing pregnancy rate per patient using their thawed embryos (independent of whether they became pregnant following a fresh embryo transfer or not10 weeks following transfer of frozen thawed embryo
implantation rate per transferred thawed embryo10 weeks after transfer of thawed embryo
ongoing pregnancy rate per frozen-thaw cycle10 weeks following thawed embryo transfer
average number of frozen-thawed cycles per patientis variable
average number of thawed embryos to ongoing implantationvariable, up to 3 years
post thaw development (categorial) per thawed embryo24 hours following thawing
Life birth rate9 month after pregnancy test
average number of cryo-thaw cycles to ongoing pregnancyvariable, up to 3 years

Trial Locations

Locations (2)

Academic Hospital of Brussels

🇧🇪

Brussels, Belgium

University Medical Center of Utrecht

🇳🇱

Utrecht, Netherlands

© Copyright 2025. All Rights Reserved by MedPath